These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Identification of a Potent and Broad-Spectrum Hepatitis C Virus Fusion Inhibitory Peptide from the E2 Stem Domain. Chi X; Niu Y; Cheng M; Liu X; Feng Y; Zheng F; Fan J; Li X; Jin Q; Zhong J; Li YP; Yang W Sci Rep; 2016 Apr; 6():25224. PubMed ID: 27121372 [TBL] [Abstract][Full Text] [Related]
26. Specific inhibition of hepatitis C virus entry into host hepatocytes by fungi-derived sulochrin and its derivatives. Nakajima S; Watashi K; Kamisuki S; Tsukuda S; Takemoto K; Matsuda M; Suzuki R; Aizaki H; Sugawara F; Wakita T Biochem Biophys Res Commun; 2013 Nov; 440(4):515-20. PubMed ID: 24099774 [TBL] [Abstract][Full Text] [Related]
27. Antiviral activity of cuprous oxide nanoparticles against Hepatitis C Virus in vitro. Hang X; Peng H; Song H; Qi Z; Miao X; Xu W J Virol Methods; 2015 Sep; 222():150-7. PubMed ID: 26116793 [TBL] [Abstract][Full Text] [Related]
28. Inhibitory Effects of Amentoflavone and Orobol on Daclatasvir-Induced Resistance-Associated Variants of Hepatitis C Virus. Lee WP; Lan KL; Liao SX; Huang YH; Hou MC; Lan KH Am J Chin Med; 2018; 46(4):835-852. PubMed ID: 29737209 [TBL] [Abstract][Full Text] [Related]
29. (-)-Epigallocatechin-3-gallate inhibits the replication cycle of hepatitis C virus. Chen C; Qiu H; Gong J; Liu Q; Xiao H; Chen XW; Sun BL; Yang RG Arch Virol; 2012 Jul; 157(7):1301-12. PubMed ID: 22491814 [TBL] [Abstract][Full Text] [Related]
30. [Research on hepatitis C virus entry inhibitor]. Zeng Wenting ; Lu X; Wang J; Jin X; Zhu J Bing Du Xue Bao; 2015 Jan; 31(1):97-105. PubMed ID: 25997338 [TBL] [Abstract][Full Text] [Related]
31. Membrane Fusion Assays for Studying Entry Hepatitis C Virus into Cells. Denolly S; Cosset FL; Freitas N Methods Mol Biol; 2019; 1911():219-234. PubMed ID: 30593629 [TBL] [Abstract][Full Text] [Related]
32. A central hydrophobic E1 region controls the pH range of hepatitis C virus membrane fusion and susceptibility to fusion inhibitors. Banda DH; Perin PM; Brown RJP; Todt D; Solodenko W; Hoffmeyer P; Kumar Sahu K; Houghton M; Meuleman P; Müller R; Kirschning A; Pietschmann T J Hepatol; 2019 Jun; 70(6):1082-1092. PubMed ID: 30769006 [TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of novel pentacyclic triterpene α-cyclodextrin conjugates as HCV entry inhibitors. Xiao S; Wang Q; Si L; Zhou X; Zhang Y; Zhang L; Zhou D Eur J Med Chem; 2016 Nov; 124():1-9. PubMed ID: 27565552 [TBL] [Abstract][Full Text] [Related]
35. The hepatitis C virus life cycle as a target for new antiviral therapies. Pawlotsky JM; Chevaliez S; McHutchison JG Gastroenterology; 2007 May; 132(5):1979-98. PubMed ID: 17484890 [TBL] [Abstract][Full Text] [Related]
36. Novel Arenavirus Entry Inhibitors Discovered by Using a Minigenome Rescue System for High-Throughput Drug Screening. Rathbun JY; Droniou ME; Damoiseaux R; Haworth KG; Henley JE; Exline CM; Choe H; Cannon PM J Virol; 2015 Aug; 89(16):8428-43. PubMed ID: 26041296 [TBL] [Abstract][Full Text] [Related]
37. Viral entry inhibition: too late for hepatitis C, but promising for other viral infections. Pawlotsky JM Gut; 2015 Mar; 64(3):362-4. PubMed ID: 25098973 [No Abstract] [Full Text] [Related]
38. Curcumin against hepatitis C virus infection: spicing up antiviral therapies with 'nutraceuticals'? Pécheur EI Gut; 2014 Jul; 63(7):1035-7. PubMed ID: 24092864 [No Abstract] [Full Text] [Related]
39. Development of a robust luciferase reporter 1b/2a hepatitis C virus (HCV) for characterization of early stage HCV life cycle inhibitors. Chan K; Robinson M; Yang H; Cornew S; Delaney Iv WE Antiviral Res; 2013 Apr; 98(1):85-92. PubMed ID: 23376631 [TBL] [Abstract][Full Text] [Related]